Non-Small Cell Lung Cancer Clinical Trial
Official title:
Multicenter Observational Study for Clinicopathological Characteristics and Clinical Efficacy of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation
Title: Multicenter observational study for clinicopathological characteristics and clinical
efficacy of Chinese Non-Small Cell Lung Cancer (NSCLC) patients With Rare Driver Gene
Mutation.
Purpose: To observe the status of rare driver gene mutations in NSCLC patients and identify
the subtypes of the mutations.
By comparing and analyzing the relationship between different subtypes, clinicopathological
features and clinical efficacy, to find out the effects on anti-tumor therapy and disease
survival.
And ultimately to promote the precise application of clinical specifications for new
anti-tumor drugs.
Study type: Observational
Inclusion criteria:
1. Female or male, 18 years of age or older;
2. Histologically or cytologically proven diagnosis of NSCLC;
3. Able to get tumor tissue gene testing results by lung cancer Polymerase Chain
Reaction(PCR)panel kit carried out in hospital
4. Signed and dated informed consent.
Exclusion criteria:
1. Combine with other tumor type
2. The investigator judges the situation that may affect the clinical search process and
results.
Estimated enrollment: 50000 participants.
Outcome measures:
Primary outcome measures:
1. The NSCLC rare driver gene mutation frequency and clinicopathological features in 50,000
patients in real world;
2. The relationship between rare driver gene subtypes and clinicopathological features
(age, gender, smoking history, histological subtype, clinical stage, lymph node
metastasis, local metastasis, distant metastasis, brain metastasis) in NSCLC patients.
Secondary outcome measures:
1. The relationship between rare driver gene mutation subtypes and disease survival or
prognosis (Objective response rate (ORR), Progression-free survival (PFS), and Overall
survival (OS)) in NSCLC patients.
Method of Research:
1. Pre- entry/screening period (V0)
1. Screen the enrolled patients according to the admission criteria. The detection of
lung cancer PCR panel kit in the hospital requires the use of tissue samples
(including surgical tissue, biopsy tissue under interventional conditions, lymph
node biopsy tissue, metastases' tissue, etc.);
2. All enrolled samples should be tested Neurotrophic-Tropomyosin Receptor Kinase
(NTRK) gene mutation (PCR);
3. If a)+b) results show a rare driver gene mutation was detected, participants will
be involved into the next step; if a)+b) test results were negative, then 500 cases
were selected for next generation sequencing (NGS) detection in this population,
and were involved into the next step;
2. Baseline period (V1)
a. Do further classification of rare driver gene mutation positive samples by Sanger
sequencing, and record the test results;
3. Follow-up period (V2)
1. Record the disease therapeutic regimen and follow-up of the survival status of the
enrolled patients;
2. Once every 3 months (or according to clinical needs) up to 60 months or death;
3. Collect information including follow-up treatment, disease status, and survival
status, imaging examination results, laboratory examination results, etc. (see the
Case Report Form (CRF) form for details);
4. For those who need further molecular testing (such as primary drug resistance),
multi-gene analysis using the next generation sequencing (NGS) method;
5. Loss of follow-up: If the patient fails to return to the center for a follow-up
visit, the center will make two attempts to contact by phone and keep the contact
records. If the patient does not respond within 1 month after the second contact,
the patient is considered to have lost the interview.
Materials and Methods:
Materials:
The specimen material must be human genomic DNA and total RNA extracted from tumor tissue
samples. Before the extraction of DNA and RNA, it is very important to make sure that there
is at least 20% tumor cells in the tumor tissue samples.
Methods:
Epidermal Growth Factor Receptor 20 exon insertion (EGFR exon 20-ins) mutation/Activin
Receptor-like Kinase (ALK) fusion/ROS proto-oncogene 1 receptor tyrosine kinase (ROS1)
fusion/Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutation/Neuroblastoma RAS viral
oncogene homolog (NRAS) mutation/B-Raf proto-oncogene, serine/threonine kinase (BRAF)
mutation/Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)
mutation/RET proto-oncogene (RET) fusion/Mesenchymal-Epithelial Transition factor (MET) 14
exon skipping/Erb-b2 Receptor Tyrosine Kinase 2 (ERBB2) mutation/ Neurotrophic-Tropomyosin
Receptor Kinase (NTRK) fusion mutation were detected by Fluorogenic Quantitative Polymerase
Chain Reaction in Chinese NSCLC.
1. DNA/RNA Extraction:
The total RNA concentration for gene fusion detection is 10~100 ng/µL in Formalin-Fixed
Paraffin-Embedded (FFPE) tissue or 2~30 ng/µL in Fresh tissue.
The amount of extracted DNA for gene mutation detection is 1.5~3 ng/µL in FFPE tissue or
0.5~1 ng/µL in Fresh tissue.
2. RNA Reverse Transcription.
3. Detection of the Target Alterations in RNA and DNA:
ALK, ROS1, RET, NTRK Gene fusion and MET 14 exon skipping mutation were detected in RNA.
EGFR 20 exon-ins, KRAS, NRAS, BRAF, PIK3CA and ERBB2 mutation were detected in DNA.
4. Result Interpretation
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |